Top 3 Health Care Stocks That May Collapse This Quarter

by | Feb 18, 2026 | General

As of Feb. 18, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.

Here’s the latest list of major overbought players in this sector.

AstraZeneca plc (NYSE:AZN)

  • On Feb. 10, AstraZeneca posted upbeat quarterly earnings. Pascal Soriot, Chief Executive Officer, AstraZeneca, said, “In 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery. We announced the results of 16 positive Phase 3 studies during the year and now have 16 blockbuster medicines.” The company’s stock gained around 14% over the past month and has a 52-week high of $211.27.
  • RSI Value: 89                                   
  • AZN Price Action: Shares of AstraZeneca gained 1.9% to close at $209.48 on Tuesday.
  • Edge Stock Ratings: 98.35 Momentum score with Value at 19.08.

Masimo Corp (NASDAQ:MASI)

  • On Feb. 17, Masimo announced it will be acquired by Danaher. Katie Szyman, Chief Executive Officer of Masimo, stated: “We look forward to joining Danaher and continuing our growth and momentum as the global leader in patient monitoring. Danaher shares our commitment to investing in talent and innovation and will be an ideal fit to help power the next chapter of Masimo. Importantly, becoming part of Danaher’s Diagnostics segment will strengthen our ability to scale our monitoring technologies globally and accelerate our mission of delivering Masimo innovations that empower clinicians to transform patient care.” The company’s stock gained around 30% over the past five days and has a 52-week high of $194.88.
  • RSI Value: 85.9
  • MASI Price Action: Shares of Masimo rose 34.2% to close at $174.69 on Tuesday.

Geron Corp (NASDAQ:GERN)

  • On Jan. 12, Geron announced FY26 financial guidance. “Our priorities for 2026 are clear – driving RYTELO® commercial growth in the U.S., pursuing paths to bring RYTELO to LR-MDS markets outside the U.S., and advancing our Phase 3 IMpactMF trial,” said Harout Semerjian, President and Chief Executive Officer of Geron. The company’s stock gained around 38% over the past month and has a 52-week high of $2.70.
  • RSI Value: 82.8
  • GERN Price Action: Shares of Geron gained 9.1% to close at $1.80 on Tuesday.

Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.

Photo via Shutterstock